AHA.18: Sacubitril-valsartan combo shows promise for acute decompensated HF

Sacubitril-valsartan therapy was associated with greater reductions in N-terminal pro-B-type natriuretic peptide (NT-proBNP) than enalapril among patients hospitalized with acute decompensated heart failure, according to research presented Nov. 11 at the American Heart Association’s Scientific Sessions and published online simultaneously in the New England Journal of Medicine.

AHA.18: VITAL, REDUCE-IT deliver mixed results for fish oil products

Fish oil pills are prescribed to patients to help reduce cardiovascular risks from atherosclerosis.

VITAL and REDUCE-IT—both highly anticipated trials revolving around the cardiovascular benefits of fish oil products—delivered mixed results at this year’s AHA Scientific Sessions in Chicago, with one trial observing few heart benefits from omega-3s while the other saw a 25 percent reduction in major cardiovascular events with a purified eicosapentaenoic acid product.

AHA.18: Nonstatin therapies, CAC testing claim larger role in cholesterol guidelines

New cholesterol guidelines from the American Heart Association and the American College of Cardiology recommend adding ezetimibe and/or PCSK9 inhibitors to statin therapy for select high-risk patients, and also propose using coronary artery calcium (CAC) scoring as “a tiebreaker” to guide statin decisions for those at intermediate risk of atherosclerotic cardiovascular disease.

Just 5% of T1D patients in UK have insured access to flash glucose monitors

Up to a quarter of type 1 diabetes patients in England should have access to the Freestyle Libre, a flash glucose monitor that allows diabetics to check their blood sugar without the need for finger pricks. But a recent investigation by the BMJ has concluded that, in reality, just 3 to 5 percent of eligible patients have access to the potentially life-changing technology.